EBR SYSTEMS, INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR - EBR SYSTEMS, INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.34

28 Jun
2022

-0.010

OPEN

$0.35

-2.86%

HIGH

$0.37

433,537

LOW

$0.34

TARGET
$1.84 441.2% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx N/A - 8.0 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

28/04/2022

1

Speculative Buy

$1.84

441.18%

First quarter results for EBR Systems were in-line with Morgans forecasts and the Speculative Buy rating and $1.84 target price are retained.

All clinical programs remain on track including the pivotal SOLVE trial, notes the analyst. Its thought further market expansion opportunities are likely from two additional, investigator led, non-randomised studies.

FORECAST
Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -8.00 cents.
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -10.00 cents.
Access Stockbroker Research History >

EBR STOCK CHART

FNArena News on EBR

1
Australian Broker Call *Extra* Edition – Apr 08, 2022

Apr 08 2022 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Feb 28, 2022

Feb 28 2022 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Jan 31, 2022

Jan 31 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Brokers Divided Over ResMed’s SaaS Acquisition

Jun 16 2022 - Australia
2
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
3
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
4
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
5
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
6
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
7
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
8
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
9
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
10
Breakout For Cochlear

Aug 10 2021 - Technicals